Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Golden Dragon Holding Co. (CPMD : OTC)

• Company Description    CannaPharmaRX, Inc. is a pharmaceutical company. The company is engaged in cannabinoid discovery, science, research & development. Cannapharmarx Inc., formerly known as Golden Dragon Holding Co., is based in Carneys Point, New Jersey. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 166,049 shares Shares Outstanding: 660.63 (millions) Market Capitalization: $2.58 (millions) Beta: 2.43 52 Week High: $0.01 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.50% -6.15% 12 Week -11.36% -25.44% Year To Date -51.85% -54.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 888 3RD STREET SW SUITE 3600 - CALGARY,A0 T2P 5C5 CAN ph: 403-637-0420 fax: 720-875-1905 info@cannapharmarx.com http://www.cannapharmarx.com

• General Corporate Information    Officers Constantine Nkafu - Chief Executive Officer Oliver Foeste - Chief Financial Officer Richard D. Orman - Director Anthony Panek - Director Elliot Zemel - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 13765D109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 660.63 Most Recent Split Date: 11.00 (0.10:1) Beta: 2.43 Market Capitalization: $2.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 100.00% Sales Growth vs. Year Ago Period: 1,188.46% vs. Previous Quarter: -30.50% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -56.69 12/31/24 - -58.97 Current Ratio 06/30/25 - - 03/31/25 - 0.05 12/31/24 - 0.04 Quick Ratio 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.00 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - 99.11 12/31/24 - -1,208.05 Book Value 06/30/25 - - 03/31/25 - -0.03 12/31/24 - -0.03 Inventory Turnover 06/30/25 - - 03/31/25 - 3.75 12/31/24 - 3.41 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©